Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm characterized by clonal proliferation of Langerhans-type dendritic cells. When LCH involves the hypothalamic-pituitary axis, it can cause significant endocrine dysfunction, diabetes insipidus, and various neurological manifestations. The impact on hypothalamic neurons and the resulting neuroendocrine disturbances represent a significant clinical challenge.
LCH represents a spectrum of disease ranging from single-system局限性 disease to multisystem involvement. Central nervous system (CNS) involvement, particularly of the hypothalamic-pituitary axis, occurs in approximately 30-50% of patients with multisystem LCH [1]. The resulting endocrine dysfunction can profoundly affect quality of life and requires long-term management.
- LCH incidence: 0.5-5 per million annually
- CNS involvement: 30-50% of multisystem cases
- Hypothalamic-pituitary axis: Most common CNS endocrine target
- Age (more common in children)
- Male predominance
- BRAF V600E mutation presence
- Multisystem disease at diagnosis
LCH results from clonal proliferation of cells bearing the phenotype of Langerhans dendritic cells:
- Cell of origin: Pre-dendritic myeloid precursor
- Key markers: CD1a+, Langerin (CD207)+, S100+
- BRAF V600E mutation: Present in ~50% of cases
- Cytokine profile: Elevated IL-1, TNF-α, IL-6
The most common CNS manifestation of LCH is diabetes insipidus caused by vasopressin (AVP) neuron dysfunction:
- Location: Typically involves the posterior pituitary and infundibulum
- Mechanism: Infiltration of AVP-producing neurons
- Clinical presentation: Polyuria, polydipsia, nocturia
- Diagnosis: Low urine osmolality, high serum osmolality, MRI findings
GH deficiency is the second most common endocrine dysfunction:
- Prevalence: 10-20% of patients with hypothalamic LCH
- Mechanism: Direct infiltration of somatotroph cells or disruption of GHRH signaling
- Clinical signs: Short stature, delayed puberty, increased fat mass
- Treatment: Recombinant GH replacement
Central hypothyroidism occurs through:
- TSH-producing neuron dysfunction
- TRH transport disruption
- Variable presentation: fatigue, weight gain, cold intolerance
Hypogonadotropic hypogonadism results from:
- GnRH neuron involvement
- LH/FSH production impairment
- Clinical features: delayed puberty, infertility, decreased libido
A subset of patients develop a neurodegenerative syndrome:
- Cerebellar ataxia: Progressive cerebellar dysfunction
- Cognitive decline: Memory and executive function impairment
- Dysarthria: Speech difficulties
- MRI findings: Cerebellar and brainstem T2 hyperintensities
- Focal seizures: Due to cortical involvement
- Generalized seizures: Secondary to metabolic disturbances
- Optic pathway involvement: Visual field defects
- Orbital LCH: Proptosis, diplopia
The BRAF V600E mutation is central to LCH pathogenesis:
| Feature |
Details |
| Prevalence |
~50% of LCH cases |
| Detection |
Immunohistochemistry, PCR, sequencing |
| Prognostic significance |
Higher recurrence risk |
| Targeted therapy |
Vemurafenib, dabrafenib |
- Constitutive MAPK signaling drives proliferation
- MEK inhibitors (trametinib) show efficacy
- ERK activation in affected neurons
- Endocrine assessment:
- 9 AM cortisol
- TSH, free T4
- LH, FSH, testosterone/estradiol
- IGF-1
- AVP testing deprivation (water test)
MRI findings:
- Enhancing masses in hypothalamic region
- Pituitary stalk thickening
- Posterior pituitary bright spot loss
- Cerebellar/brainstem T2 hyperintensities (neurodegenerative)
- CD1a positive cells
- Langerin (CD207) positivity
- Birbeck granules on electron microscopy (lollipop-shaped)
| Deficiency |
Treatment |
| Diabetes insipidus |
Desmopressin (DDAVP) |
| Growth hormone |
Recombinant GH |
| Hypothyroidism |
Levothyroxine |
| Hypogonadism |
Sex steroid replacement |
| Adrenal insufficiency |
Glucocorticoid replacement |
- First-line: Vinblastine + prednisone
- Refractory: Cytarabine, cladribine (2-CdA)
- BRAF inhibitor: Vemurafenib for BRAF V600E+
- MEK inhibitor: Trametinib for refractory cases
- Immunotherapy: Anti-PD1, anti-PDL1
- Targeted therapy: Combination BRAF + MEK inhibition
- Stem cell transplantation: For high-risk disease
- Single-system LCH: <5%
- Multisystem LCH without CNS: 10-15%
- Multisystem LCH with CNS: 20-30%
- Permanent endocrine dysfunction: 40-60%
- Neurocognitive deficits: 20-30%
- Neurodegenerative syndrome: 5-10%
- Secondary malignancies: 5%
- BRAF/MEK inhibitors: Targeted approaches for refractory disease
- Immunotherapy: Checkpoint inhibitors
- Gene therapy: Future potential for AVP deficiency
- Circulating tumor DNA
- CSF cytokine profiles
- Metabolic markers
- Grois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006
- Makras P, Alexandraki KI, Chrousos GP, et al. Endocrine manifestations of Langerhans cell histiocytosis. Horm Metab Res. 2008
- Bernstein A, Mistry R, Mandeville J. Langerhans cell histiocytosis: A clinicopathological review. J Clin Pathol. 2020
- Hutter C, Minkov M. Insights into the pathogenesis of Langerhans cell histiocytosis: The role of BRAF and MAPK pathway. J Pediatr Hematol Oncol. 2018
- Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010